Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015732 | 0.78 | OPRL1 (0.59) | OPRM1OPRL1OPRK1SIGMAR1 | |
| SCHEMBL1119687 | 0.76 | OPRM1 (0.51) | OPRM1OPRL1OPRK1SIGMAR1 | |
| SCHEMBL23878715 | 0.75 | SIGMAR1 (0.60) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8704495 | 0.74 | OPRL1 (0.57) | OPRL1SIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL11883601 | 0.74 | SIGMAR1 (0.51) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14601364 | 0.74 | OPRM1 (0.76) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3205899 | 0.72 | OPRL1 (0.47) | OPRM1OPRL1OPRK1SIGMAR1CHRM2 | |
| SCHEMBL3216799 | 0.72 | OPRM1 (0.47) | OPRM1OPRL1OPRK1CHRM2CHRM4 | |
| SCHEMBL735261 | 0.72 | OPRL1 (0.46) | OPRM1OPRL1OPRK1 | |
| SCHEMBL29892064 | 0.71 | SIGMAR1 (0.51) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678834-B2 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2010-03-16 | — | — | US | claimed |
| EP-1406859-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-01-02 | — | — | EP | claimed |
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| EP-1406859-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003008371-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | claimed |
| US-7678834-B2 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2010-03-16 | — | — | US | disclosed |
| EP-1406859-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-01-02 | — | — | EP | disclosed |
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1406859-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003008371-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | ADRA2C, OPRD1, OPRK1 | OPRM1 6/4885OPRL1 4/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.